These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Early detection and response to meningococcal disease epidemics in sub-Saharan Africa: appraisal of the WHO strategy. Leake JA; Kone ML; Yada AA; Barry LF; Traore G; Ware A; Coulibaly T; Berthe A; Mambu Ma Disu H; Rosenstein NE; Plikaytis BD; Esteves K; Kawamata J; Wenger JD; Heymann DL; Perkins BA Bull World Health Organ; 2002; 80(5):342-9. PubMed ID: 12077608 [TBL] [Abstract][Full Text] [Related]
26. Continuing risk of meningitis due to Neisseria meningitidis serogroup C in Africa: revised recommendations from a WHO expert consultation. Wkly Epidemiol Rec; 2017 Oct; 92(41):612-7. PubMed ID: 29028166 [No Abstract] [Full Text] [Related]
27. [Impact of a conjugated anti meningococcal A vaccine on notification of bacterial meningitis in West Burkina Faso (2009-2012)]. Ouangraoua S; Schlumberger M; Yaro S; Ouédraogo AS; Sanou S; Drabo A; Yaméogo TM; Ouedraogo R Bull Soc Pathol Exot; 2014 Feb; 107(1):27-30. PubMed ID: 24390976 [TBL] [Abstract][Full Text] [Related]
28. Priority during a meningitis epidemic: vaccination or treatment? Veeken H; Ritmeijer K; Hausman B Bull World Health Organ; 1998; 76(2):135-41. PubMed ID: 9648353 [TBL] [Abstract][Full Text] [Related]
29. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Boisier P; Nicolas P; Djibo S; Taha MK; Jeanne I; Maïnassara HB; Tenebray B; Kairo KK; Giorgini D; Chanteau S Clin Infect Dis; 2007 Mar; 44(5):657-63. PubMed ID: 17278055 [TBL] [Abstract][Full Text] [Related]
34. Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso. Vogel G Science; 2003 Mar; 299(5612):1499-501. PubMed ID: 12624241 [No Abstract] [Full Text] [Related]
35. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435 [TBL] [Abstract][Full Text] [Related]
36. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Bishai DM; Champion C; Steele ME; Thompson L Health Aff (Millwood); 2011 Jun; 30(6):1058-64. PubMed ID: 21653957 [TBL] [Abstract][Full Text] [Related]
37. The implications of vaccines for prevention of bacterial meningitis. Riordan A Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637 [TBL] [Abstract][Full Text] [Related]
38. [Neisseria meningitidis and meningitis]. Nicolas P; Debonne JM; Martet G Med Trop (Mars); 1999; 59(1):68-78. PubMed ID: 10472587 [TBL] [Abstract][Full Text] [Related]
39. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Weiss D; Stern EJ; Zimmerman C; Bregman B; Yeung A; Das D; Dentinger CM; Marx MA; Kornblum J; Lee L; Halse TA; Mayer LW; Hatcher CP; Theodore MJ; Schmink S; Harcourt BH; Zucker JR; Layton M; Clark TA; Clin Infect Dis; 2009 Apr; 48(7):894-901. PubMed ID: 19231975 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Soriano-Gabarró M; Toé L; Tiendrebeogo SR; Nelson CB; Dabal M; Djingarey MH; Plikaytis B; Rosenstein N; Vaccine; 2007 Sep; 25 Suppl 1():A92-6. PubMed ID: 17517451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]